Misillan

Misillan is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the development of innovative therapies for metabolic diseases. The company focuses on multi-receptor agonists, including GLP-1, GIP, and glucagon receptor (GCGR) targets, to treat conditions such as obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). Its lead candidate, MSL-007, is a long-acting GLP-1/GIP dual agonist currently undergoing clinical evaluation for weight management and glycemic control. Misillan leverages a proprietary technology platform to design optimized peptide and protein drugs with improved efficacy, safety, and pharmacokinetic profiles. The company was founded by industry veterans with extensive experience in metabolic research and is backed by prominent venture capital firms.